더바이오 11월 6일 주요뉴스

[https://www.thebionews.net/edit/webzine.html?idxno=678](https://www.thebionews.net/edit/webzine.html?idxno=678)

● [단독] MSD·한미 ‘에피노페그듀타이드’, 2b상 성공…“MASH 해소율 63%·섬유화 개선율 52%”
[https://www.thebionews.net/news/articleView.html?idxno=29922](https://www.thebionews.net/news/articleView.html?idxno=29922)

● “적자가 죄는 아니다”…바이오업계, 기술특례상장 ‘법차손 규제’ 개선 촉구
[https://www.thebionews.net/news/articleView.html?idxno=29921](https://www.thebionews.net/news/articleView.html?idxno=29921)

● 한미약품 자회사 앱토즈, ‘투스페티닙’ AML 임상1·2상서 반응률 81.8%
[https://www.thebionews.net/news/articleView.html?idxno=29926](https://www.thebionews.net/news/articleView.html?idxno=29926)

● 한미 기술이전 ‘포셀티닙’ 3제 병용, DLBCL 2상 ORR 83.5%·CR 비율 59.5%
[https://www.thebionews.net/news/articleView.html?idxno=29925](https://www.thebionews.net/news/articleView.html?idxno=29925)

● 식약처, ‘첨단바이오의약품’ 등 허가 수수료 현실화…최대 6.2배 인상 추진
[https://www.thebionews.net/news/articleView.html?idxno=29957](https://www.thebionews.net/news/articleView.html?idxno=29957)

● 사노피, 알테오젠 ‘ALT-B4’ 적용 듀피젠트 SC 제형 임상3상 추진
[https://www.thebionews.net/news/articleView.html?idxno=29936](https://www.thebionews.net/news/articleView.html?idxno=29936)

● 메타비아, ‘DA-1726’ 지방간·체중 동시 감소 확인…내년 임상2상 추진
[https://www.thebionews.net/news/articleView.html?idxno=29938](https://www.thebionews.net/news/articleView.html?idxno=29938)

● 제노스코, ROCK2 억제제 ‘GNS-3545’ 임상1상 완료…"2상·기술이전 추진"
[https://www.thebionews.net/news/articleView.html?idxno=29940](https://www.thebionews.net/news/articleView.html?idxno=29940)

● 美에보뮨, 中히노바서 VAV1 표적 분자접착분해제 도입…최대 1.5조원 규모
[https://www.thebionews.net/news/articleView.html?idxno=29960](https://www.thebionews.net/news/articleView.html?idxno=29960)

● 한미약품, 두 번째 ‘BID’ 개최…‘삼성증권’과 신약·AI 벤처 투자 연결
[https://www.thebionews.net/news/articleView.html?idxno=29955](https://www.thebionews.net/news/articleView.html?idxno=29955)

● 美 아밀릭스, ‘비만 수술 후 저혈당증’ 신약 임상3상 성공…연내 FDA 허가 신청
[https://www.thebionews.net/news/articleView.html?idxno=29949](https://www.thebionews.net/news/articleView.html?idxno=29949)

● 인텔리아, 세계 첫 체내 CRISPR 치료제 내년 3월 美 허가 목표…4억달러 조달
[https://www.thebionews.net/news/articleView.html?idxno=29948](https://www.thebionews.net/news/articleView.html?idxno=29948)

● 오스코텍 최대주주 김성연 “이사회 장악 아냐…제노스코 인수 안건서 빠질 것”
[https://www.thebionews.net/news/articleView.html?idxno=29972](https://www.thebionews.net/news/articleView.html?idxno=29972)

● 파마리서치, 해외 사업 호조 3Q 매출 1715억원…전년比 27% 증가
[https://www.thebionews.net/news/articleView.html?idxno=29945](https://www.thebionews.net/news/articleView.html?idxno=29945)

● 씨젠, 3Q 영업익 116억원·21.2% 증가…비호흡기 제품 매출 전년比 12.3%↑
[https://www.thebionews.net/news/articleView.html?idxno=29970](https://www.thebionews.net/news/articleView.html?idxno=29970)

● 지씨셀, ‘CD5 CAR-NK’ T세포 림프종 1a상 반응률 52.9%·완전관해 29.4%
[https://www.thebionews.net/news/articleView.html?idxno=29927](https://www.thebionews.net/news/articleView.html?idxno=29927)

● 아이엠지티, 美 UVA서 ‘췌장암’ 임상 첫 환자 등록…글로벌 확증임상 본격화
[https://www.thebionews.net/news/articleView.html?idxno=29934](https://www.thebionews.net/news/articleView.html?idxno=29934)

● 라메디텍, 스킨부스터 특화 레이저 의료기기 ‘레인젯’ 식약처 허가
[https://www.thebionews.net/news/articleView.html?idxno=29958](https://www.thebionews.net/news/articleView.html?idxno=29958)

●인벤테라, LG화학과 췌담관 조영제 신약 후보 ‘INV-003’ API 생산 계약
[https://www.thebionews.net/news/articleView.html?idxno=29947](https://www.thebionews.net/news/articleView.html?idxno=29947)

● “美·佛·獨 세계 각국 1위 암병원, 삼성서울병원에서 모인다”
[https://www.thebionews.net/news/articleView.html?idxno=29929](https://www.thebionews.net/news/articleView.html?idxno=29929)

● ﻿World's top cancer hospitals from U.S., France, and Germany converge at Samsung Medical Center
[https://www.thebionews.net/news/articleView.html?idxno=29968](https://www.thebionews.net/news/articleView.html?idxno=29968)

● ﻿﻿MetaVia confirms simultaneous fatty liver and body weight reduction with ‘DA-1726,’ plans Phase 2 clinical trials next year
[https://www.thebionews.net/news/articleView.html?idxno=29965](https://www.thebionews.net/news/articleView.html?idxno=29965)

● Sanofi moves ahead with Phase 3 clinical trials for Dupixent SC formulation using Alteogen’s ‘ALT-B4’
[https://www.thebionews.net/news/articleView.html?idxno=29964](https://www.thebionews.net/news/articleView.html?idxno=29964)

● ﻿﻿﻿﻿﻿﻿﻿Inventera inks API production deal with LG Chem for novel pancreaticobiliary contrast agent candidate ‘INV-003’
[https://www.thebionews.net/news/articleView.html?idxno=29963](https://www.thebionews.net/news/articleView.html?idxno=29963)

● ﻿SK Biopharmaceuticals expands U.S. PGTC treatment reach with ‘cenobamate,’ maximizing new drug value
[https://www.thebionews.net/news/articleView.html?idxno=29953](https://www.thebionews.net/news/articleView.html?idxno=29953)

● ﻿﻿﻿Bion Liquid launches ‘liquid protective barrier’ development to protect RNA, uncovering 17 low-toxicity materials
[https://www.thebionews.net/news/articleView.html?idxno=29952](https://www.thebionews.net/news/articleView.html?idxno=29952)

● ﻿JW Pharmaceutical posts KRW 211.1 billion Q3 revenue on strong ‘Livalozet’ sales, up 6.3% year-on-year
[https://www.thebionews.net/news/articleView.html?idxno=29951](https://www.thebionews.net/news/articleView.html?idxno=29951)

● ﻿Samsung Medical Center registers U.S. patent for data-driven hospital operations technology, following Europe
[https://www.thebionews.net/news/articleView.html?idxno=29950](https://www.thebionews.net/news/articleView.html?idxno=29950)

*제약바이오 11월 6일 아침 유튜브 라디오 뉴스(매일 아침 업로드)
[https://www.youtube.com/watch?v=--l_qKJOh48](https://www.youtube.com/watch?v=--l_qKJOh48)